Health-Related Quality of Life in Non-Small-Cell Lung Cancer: An Update of a Systematic Review on Methodologic Issues in Randomized Controlled Trials

被引:78
作者
Claassens, Lily
van Meerbeeck, Jan
Coens, Corneel
Quinten, Chantal
Ghislain, Irina
Sloan, Elizabeth K.
Wang, Xin Shelly
Velikova, Galina
Bottomley, Andrew
机构
[1] Erasmus MC, Rotterdam, Netherlands
[2] Ghent Univ Hosp, B-9000 Ghent, Belgium
[3] European Org Res & Treatment Canc Headquarters, Brussels, Belgium
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Leeds, St Jamess Inst Oncol, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
关键词
PHASE-III TRIAL; GEMCITABINE PLUS CARBOPLATIN; SINGLE-AGENT GEMCITABINE; POOR PERFORMANCE STATUS; PLATINUM-BASED CHEMOTHERAPY; CLINICAL DECISION-MAKING; ELDERLY-PATIENTS; STANDARD CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; 1ST-LINE CHEMOTHERAPY;
D O I
10.1200/JCO.2010.32.3683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study is an update of a systematic review of health-related quality-of-life (HRQOL) methodology reporting in non-small-cell lung cancer (NSCLC) randomized controlled trials (RCTs). The objective was to evaluate HRQOL methodology reporting over the last decade and its benefit for clinical decision making. Methods A MEDLINE systematic literature review was performed. Eligible RCTs implemented patient-reported HRQOL assessments and regular oncology treatments for newly diagnosed adult patients with NSCLC. Included studies were published in English from August 2002 to July 2010. Two independent reviewers evaluated all included RCTs. Results Fifty-three RCTs were assessed. Of the 53 RCTs, 81% reported that there was no significant difference in overall survival (OS). However, 50% of RCTs that were unable to find OS differences reported a significant difference in HRQOL scores. The quality of HRQOL reporting has improved; both reporting of clinically significant differences and statistical testing of HRQOL have improved. A European Organisation for Research and Treatment of Cancer HRQOL questionnaire was used in 57% of the studies. However, reporting of HRQOL hypotheses and rationales for choosing HRQOL instruments were significantly less than before 2002 (P < .05). Conclusion The number of NSCLC RCTs incorporating HRQOL assessments has considerably increased. HRQOL continues to demonstrate its importance in RCTs, especially in those studies in which no OS difference is found. Despite the improved quality of HRQOL methodology reporting, certain aspects remain underrepresented. Our findings suggest need for an international standardization of HRQOL reporting similar to the CONSORT guidelines for clinical findings.
引用
收藏
页码:2104 / 2120
页数:17
相关论文
共 89 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
[Anonymous], 2008, Cancer Facts Figures 2008
[3]   Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data [J].
Auperin, A. ;
Le Chevalier, T. ;
Le Pechoux, C. ;
Pignon, J. P. ;
Tribodet, H. ;
Burdett, S. ;
Stewart, L. A. ;
Tierney, J. F. ;
Stephens, R. J. ;
Arriagada, R. ;
Higgins, J. P. ;
Johnson, D. H. ;
van Meerbeeck, J. ;
Parmar, M. K. B. ;
Souhami, R. L. ;
Bergman, B. ;
Dautzenberg, B. ;
Douillard, J. Y. ;
Dunant, A. ;
Endo, C. ;
Girling, D. J. ;
Imaizumi, M. ;
Kato, H. ;
Keller, S. M. ;
Kimura, H. ;
Knuuttila, A. ;
Kodama, K. ;
Komaki, R. ;
Kris, M. G. ;
Lad, T. ;
Mineo, T. ;
Park, J. H. ;
Piantadosi, S. ;
Pyrhonen, S. ;
Rosell, R. ;
Scagliotti, G. V. ;
Seymour, L. W. ;
Shepherd, F. A. ;
Spiro, S. G. ;
Strauss, G. M. ;
Sylvester, R. ;
Tada, H. ;
Tanaka, F. ;
Torri, V. ;
Wada, H. ;
Waller, D. ;
Xu, G. C. .
LANCET, 2010, 375 (9722) :1267-1277
[4]   Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small-cell lung cancer [J].
Baka, S ;
Ashcroft, L ;
Anderson, H ;
Lind, M ;
Burt, P ;
Stout, R ;
Dowd, I ;
Smith, D ;
Lorigan, P ;
Thatcher, N .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2136-2144
[5]   Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life - A randomized controlled trial [J].
Belani, Chandra P. ;
Pereira, Jose R. ;
von Pawel, Joachim ;
Pluzanska, Anna ;
Gorbounova, Vera ;
Kaukel, Eckhard ;
Mattson, Karin V. ;
Ramlau, Rodryg ;
Szczesna, Aleksandra ;
Fidias, Panos ;
Millward, Michael ;
Fossella, Frank .
LUNG CANCER, 2006, 53 (02) :231-239
[6]   Randomized phase III trial comparing cisplatin-etoposide to carhoplatin-paclitaxel in advanced or metastatic non-small cell lung cancer [J].
Belani, CP ;
Lee, JS ;
Socinski, MA ;
Robert, F ;
Waterhouse, D ;
Rowland, K ;
Ansari, R ;
Lilenbaum, R ;
Natale, RB .
ANNALS OF ONCOLOGY, 2005, 16 (07) :1069-1075
[7]   THE EORTC QLQ-LC13 - A MODULAR SUPPLEMENT TO THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) FOR USE IN LUNG-CANCER CLINICAL-TRIALS [J].
BERGMAN, B ;
AARONSON, NK ;
AHMEDZAI, S ;
KAASA, S ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :635-642
[8]   Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non-Small-Cell Lung Cancer: Results From a Randomized Trial, JBR. 10 [J].
Bezjak, Andrea ;
Lee, Christopher W. ;
Ding, Keyue ;
Brundage, Michael ;
Winton, Timothy ;
Graham, Barbara ;
Whitehead, Marlo ;
Johnson, David H. ;
Livingston, Robert B. ;
Seymour, Lesley ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (31) :5052-5059
[9]   A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) [J].
Booton, R. ;
Lorigan, P. ;
Anderson, H. ;
Baka, S. ;
Ashcroft, L. ;
Nicolson, M. ;
O'Brien, M. ;
Dunlop, D. ;
O'Byrne, K. ;
Laurence, V. ;
Snee, M. ;
Dark, G. ;
Thatcher, N. .
ANNALS OF ONCOLOGY, 2006, 17 (07) :1111-1119
[10]   Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials [J].
Bottomley, A ;
Efficace, F ;
Thomas, R ;
Vanvoorden, V ;
Ahmedzai, SH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2982-2992